Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH‐agonists in ovarian cancer
Authors:
- 1 January 1992
- journal article
- review article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 71 (S155) , 31-38
Abstract
During the last two decades, considerable experimental evidence has been collected indicating that epithelial ovarian cancer might be gonadotropin dependent. LH and FSH receptors have been described in some of these tumors. The proliferation of ovarian cancer cells could be stimulated in vitro by gonadotropins. Suppression of endogenous LH and FSH secretion by GnRH‐agonist treatment inhibited the growth of experimental or heterotransplanted ovarian cancers in various animal models. A number of recent phase II clinical trials have shown that the application of GnRH‐agonists can lead to remission or stable disease in patients with relapsed advanced ovarian cancer. At present, prospective controlled clinical studies are being performed to assess the efficacy of GnRH‐agonist treatment in addition to conventional surgical and cytostatic therapy in ovarian cancer in FIGO stages III and IV. Also, direct effects of GnRH analogues on ovarian cancer seem possible: a GnRH‐like protein has been found in the human ovary. Our group discovered and partially characterized a specific GnRH‐binding site (mol. wt 63.2 kDa) in ovarian cancer which is very similar to other human extrapituitary GnRH‐binding sites of the low affinity, high capacity type, e.g. in breast cancer or the placenta. Recently, other groups have described also high affinity GnRH‐agonist binding sites in ovarian cancer as well as in other extrapituitary tissues. First results from our laboratory indicate that the proliferation of certain ovarian cancer cell lines in vitro is reduced by both agonistic and antagonistic analogues of GnRH. Other authors were able to inhibit gonadotropin‐induced in vitro proliferation of ovarian cancer cell lines by co‐incubation with a GnRH‐agonist. Thus GnRH ‐ or a related compound ‐ might act as an autocrine regulator of ovarian cancer proliferation, a finding which might be useful for the development of new therapeutic approaches.Keywords
Funding Information
- Stiftung P. E. Kempkes
- Alfred and Ursula Kuhlemann Stiftung
- Ferring Arzneimittel GmbH, Kiel, FRG
This publication has 49 references indexed in Scilit:
- Steroid Hormones Modulate the Release of Immunoreactive Gonadotropin-Releasing Hormone from Cultured Human Placental Cells*The Journal of Clinical Endocrinology & Metabolism, 1990
- Cancer of the breast and reproductive tract in relation to use of oral contraceptivesContraception, 1989
- Reproductive factors and risk of ovarian cancer: A prospective studyInternational Journal of Cancer, 1988
- Characterization of a Gonadotropin-Releasing Hormone Receptor Site in Term Placenta and Chorionic VilliThe Journal of Clinical Endocrinology & Metabolism, 1986
- Luteinizing Hormone-Releasing Hormone Binds to Enriched Human Placental Membranes and Stimulates in Vitro the Synthesis of Bioactive Human Chorionic Gonadotropin*The Journal of Clinical Endocrinology & Metabolism, 1984
- Identification of luteinizing hormone‐releasing factor and alpha subunit of glycoprotein hormones in ductal carcinoma of the mammary glandInternational Journal of Cancer, 1980
- Placental Luteinizing Hormone-Releasing Factor and Its SynthesisScience, 1980
- "INCESSANT OVULATION" AND OVARIAN CANCERThe Lancet, 1979
- The etiology and prevention of ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1975
- INCESSANT OVULATION—A FACTOR IN OVARIAN NEOPLASIA ?The Lancet, 1971